Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research

Study Design

Type
Systematic Review
Sample size
n = 463
Population
1,463 patients with plaque psoriasis
Methods
A network meta-analysis (NMA) of 21 randomized controlled trials (RCTs) ... using eight international and Chinese databases up to March 3, 2025. Interventions included vitamin D, XP-828L, fish oil, selenium, probiotics, curcumin, and micronutrients.

Background

Psoriasis, a chronic immune-mediated inflammatory skin disease, significantly impairs quality of life. Conventional treatments often pose safety risks or lack long-term efficacy. Dietary supplements show immunomodulatory and anti-inflammatory effects, but their adjunctive role in plaque psoriasis lacks a comprehensive comparison.

Methods

A network meta-analysis (NMA) of 21 randomized controlled trials (RCTs), involving 1,463 patients with plaque psoriasis, was conducted using eight international and Chinese databases up to March 3, 2025. Interventions included vitamin D, XP-828L, fish oil, selenium, probiotics, curcumin, and micronutrients. Primary outcomes were Psoriasis Area and Severity Index (PASI), Dermatology Life Quality Index (DLQI), physician global assessment (PGA), interleukins (IL-6, IL-17, IL-23, IL-22), and adverse events. A frequentist NMA in Stata 17.0 used surface under the cumulative ranking curve (SUCRA) to rank efficacy and safety.

Results

In 21 RCTs (n = 1,463), vitamin D supplementation significantly reduced PASI scores (mean difference = -3.29, 95% confidence interval [CI] - 6.38 to -0.20). XP-828L showed the highest probability of improving DLQI/PGA, and vitamin D + NB-UVB most consistently lowered IL-6/IL-17/IL-23; curcumin reduced IL-22. Adverse events were comparable across interventions (risk ratio 1.02, 95% CI 0.94-1.10). No supplement dominated across all outcomes, and overall certainty was low-to-moderate due to heterogeneity and imprecision.

Conclusion

Dietary supplements may provide complementary benefits in plaque psoriasis; however, effect estimates vary by outcome, and certainty is low to moderate. Personalization is advisable, and confirmatory, larger RCTs with standardized dosing and longer follow-up are warranted. (Word count: 223).

Systematic review registration

The review was registered at INPLASY (INPLASY202570119; DOI:10.37766/inplasy2025.7.0119).

Research Insights

Adverse Events Reported

  • Vitamin DOverall tolerability

    Adverse events were comparable across interventions (risk ratio 1.02, 95% CI 0.94-1.10).

    Finding
    No significant difference
    Magnitude
    risk ratio 1.02, 95% CI 0.94-1.10
    Significant
    No
  • TurmericOverall tolerability

    Adverse events were comparable across interventions (risk ratio 1.02, 95% CI 0.94-1.10).

    Finding
    No significant difference
    Magnitude
    risk ratio 1.02, 95% CI 0.94-1.10
    Significant
    No
Back to top